CureVac (NASDAQ:CVAC) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. trimmed its position in CureVac (NASDAQ:CVAC - Free Report) by 43.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 440,509 shares of the company's stock after selling 339,496 shares during the quarter. Point72 Asset Management L.P. owned about 0.20% of CureVac worth $1,502,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in CureVac in the fourth quarter valued at approximately $585,000. Alyeska Investment Group L.P. raised its position in CureVac by 25.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company's stock valued at $1,705,000 after purchasing an additional 100,000 shares during the period. Northern Trust Corp lifted its stake in shares of CureVac by 98.1% in the 4th quarter. Northern Trust Corp now owns 60,100 shares of the company's stock valued at $205,000 after purchasing an additional 29,759 shares during the last quarter. Barclays PLC acquired a new position in shares of CureVac in the 3rd quarter valued at $67,000. Finally, Geode Capital Management LLC grew its holdings in shares of CureVac by 10.3% during the 4th quarter. Geode Capital Management LLC now owns 241,750 shares of the company's stock worth $824,000 after purchasing an additional 22,491 shares during the period. Hedge funds and other institutional investors own 17.26% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on CVAC shares. UBS Group reduced their price objective on shares of CureVac from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. JMP Securities reissued a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a research note on Friday, February 14th.

CureVac Stock Down 8.9%

NASDAQ:CVAC opened at $3.90 on Thursday. CureVac has a 52 week low of $2.37 and a 52 week high of $5.28. The stock's fifty day moving average is $3.20 and its two-hundred day moving average is $3.27. The stock has a market capitalization of $874.92 million, a price-to-earnings ratio of 7.09 and a beta of 2.43. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.

CureVac (NASDAQ:CVAC - Get Free Report) last posted its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The firm had revenue of $15.44 million for the quarter, compared to analyst estimates of $6.40 million. Research analysts anticipate that CureVac will post 0.72 EPS for the current year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

Want to see what other hedge funds are holding CVAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CureVac (NASDAQ:CVAC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.